Product image of Levosimendan Kalceks (Levosimendan) supplied by GNH India

Levosimendan Kalceks

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Kalceks (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer and potassium‑channel opener presented as an intravenous solution for intravenous use. It is indicated for the treatment of acute decompensated heart failure and cardiogenic shock in adult patients. It is used under medical supervision in critical care settings.

GNH India supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and intensive‑care pharmacies worldwide, ensuring quality and regulatory compliance. The company provides full documentation and support for import and distribution.

Manufacturer / TM Owner

Kalceks

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Levosimendan is a calcium sensitizer and potassium‑channel opener used in the management of severe heart‑failure syndromes.

  • Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.
  • Cardiogenic shock: stabilizes hemodynamics and supports organ perfusion.
  • Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility and facilitates weaning from mechanical support.

How It Works

  • Levosimendan binds to troponin C in cardiac myocytes, increasing the sensitivity of the contractile apparatus to calcium and thereby augmenting inotropy without raising intracellular calcium concentrations. It simultaneously opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation that lowers preload and afterload, which together improve cardiac performance.

Side Effects

Levosimendan may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects

  • Hypotension: drop in blood pressure, especially after rapid infusion.
  • Headache: mild to moderate intensity.
  • Nausea or vomiting: gastrointestinal upset.
  • Dizziness or tachycardia: transient increase in heart rate.

Serious or Rare Side Effects

  • Severe hypotension: may require vasopressor support.
  • Arrhythmias: ventricular tachycardia, atrial fibrillation, or other rhythm disturbances.
  • Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.

Precautions & Warnings

Levosimendan requires careful monitoring in several clinical situations.

  • Renal impairment: adjust monitoring as drug clearance may be reduced.
  • Hepatic dysfunction: use with caution due to altered metabolism.
  • Hypotension: monitor blood pressure closely during and after infusion.
  • Concurrent vasodilators: risk of additive blood‑pressure lowering effects.
  • History of arrhythmia: continuous ECG surveillance recommended.
  • Pregnancy and lactation: safety not established; avoid unless clearly indicated.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid)

  • Sodium nitroprusside: additive vasodilation may cause severe hypotension.
  • Other calcium sensitizers: combined inotropic effect can lead to excessive cardiac stimulation.
  • Additional potassium‑channel openers: synergistic vasodilatory response.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt desired hemodynamic response.
  • ACE inhibitors or ARBs: can enhance blood‑pressure lowering effect.
  • Diuretics: may predispose to electrolyte disturbances, especially potassium shifts.

Frequently Asked Questions

Levosimendan Kalceks is an intravenous formulation of levosimendan used primarily to treat acute decompensated heart failure and cardiogenic shock in adult patients, helping to improve cardiac output and stabilize hemodynamics.

Levosimendan increases the sensitivity of cardiac muscle fibers to calcium by binding to troponin C, which enhances contractility without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac workload.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient’s condition, severity of heart failure, and response to therapy. Specific infusion rates and duration are individualized and should follow local prescribing guidelines.

Safety data for levosimendan in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended before use in these populations.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without increasing intracellular calcium, which may reduce the risk of arrhythmias. It also provides vasodilatory effects through potassium‑channel opening, offering a combined inotropic and vasodilatory profile that differs from agents such as dobutamine.

Levosimendan Kalceks should be stored refrigerated at 2‑8 °C. Keep the solution in its original container, protect it from light, and avoid freezing or shaking to maintain stability and potency.

Levosimendan is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed under close clinical monitoring in a hospital or intensive‑care setting.

The most serious risks include severe hypotension, potentially life‑threatening arrhythmias, and myocardial ischemia. Patients should be monitored continuously for blood‑pressure changes, cardiac rhythm disturbances, and signs of inadequate coronary perfusion during therapy.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, uncontrolled severe hypotension, or those receiving other potent vasodilators that could precipitate dangerous blood‑pressure drops. Caution is also advised in individuals with severe hepatic or renal impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT